Ultomiris approved in the US for adults with generalised myasthenia gravis
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim
To extend the nationwide distribution network for the availability of its proprietary & award-winning HPod for corporates & doctors’ clinics, thereby strengthening India’s phygital wellness ecosystem
The plant is expected to start commercial operations from Q4FY24
Glenmark Pharmaceuticals won Innovation of the Year award
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Subscribe To Our Newsletter & Stay Updated